803 related articles for article (PubMed ID: 16813888)
1. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
[TBL] [Abstract][Full Text] [Related]
2. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
[TBL] [Abstract][Full Text] [Related]
3. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center.
Freedland SJ; Grubb KA; Yiu SK; Humphreys EB; Nielsen ME; Mangold LA; Isaacs WB; Partin AW
J Urol; 2005 Sep; 174(3):919-22. PubMed ID: 16093988
[TBL] [Abstract][Full Text] [Related]
4. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
5. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score?
Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL; Freedland SJ
J Urol; 2006 Dec; 176(6 Pt 1):2453-8; discussion 2458. PubMed ID: 17085127
[TBL] [Abstract][Full Text] [Related]
6. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
7. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
[TBL] [Abstract][Full Text] [Related]
8. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
9. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
10. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
11. Is a positive bladder neck margin truly a T4 lesion in the prostate specific antigen era? Results from the SEARCH Database.
Buschemeyer WC; Hamilton RJ; Aronson WJ; Presti JC; Terris MK; Kane CJ; Amling CL; Freedland SJ
J Urol; 2008 Jan; 179(1):124-9; discussion 129. PubMed ID: 17997433
[TBL] [Abstract][Full Text] [Related]
12. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
13. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
14. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
J Urol; ; . PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]